(NaturalNews) Melinda Gates has just unrolled her new program to reduce population in Africa and South Asia. Speaking at the Family Planning Summit in London, the other half of the Gates-Messiah operation pledged to bring contraception to millions of women and girls in the Third World.
Flying under the radar; however, is the partnership between
The Gates Foundation and drug giant, Pfizer, and therein lies the dirty little secret.
The method of choice to prevent births? Injectable Depo-Provera, long known as a highly dangerous drug. It actually carries a black-box warning on its label, stating that severe bone loss is a consequence of its use. It also thins the vaginal lining, and research is ongoing to investigate the possibility that it increases the risk of breast cancer.
Here is the relevant black-box quote: "Women who use Depro-Provera Contraceptive Injection may lose significant bone mineral density. Bone loss is greater with increased duration of use and may not be completely reversible."
Change.org and several other groups are petitioning the US Congress to cut all federal funding for Depo-Provera.
Despite cheerful PR about education of women on the benefits of contraception, and the need for informed consent, these programs have a way of turning into something else out in the field, where the needle meets the body.
Depo-Provera also happens to be a drug of choice for the "chemical castration" of male sex offenders. That fact testifies to its powerful impact on the body.
Nobody at the London Family Planning Summit was talking about Depo-Provera and its severe effects. The conference sponsors, the UN Population Fund, the USAID, and
The Gates Foundation, are far more interested in population control.
If millions of girls and women in
Africa and South Asia are crippled by the Depo-Provera injections, well, that's just collateral damage. Several years from now, we'll no doubt see studies claiming an unexplained epidemic of osteoporosis in the Third World, which will lead to the application of some other highly toxic
drug as the treatment of choice.
Pfizer, the maker of Depo-Provera, happens to make such a drug: Fablyn (Lasofoxifene). So far, the FDA has withheld approval, but the EU gave it the green light in 2009. Fablyn has a serious problem. It causes blood clots in veins, which can be life-threatening.
Watch out, Africa. Melinda's coming with Pfizer. You should ask her why she doesn't supply money to clean up contaminated water supplies, install rudimentary sanitation, provide real nutrition, and help restore stolen fertile land to local farmers.
But you see, those actions aren't in line with the elite agenda. They make things better. The agenda is dedicated to Worse.
Sources:http://www.reuters.comhttp://www.change.orghttp://www.path.org/news/pr120711-depo-uniject.phpJon RappoportThe author of an explosive new collection, THE MATRIX REVEALED, Jon was a candidate for a US Congressional seat in the 29th District of California. Nominated for a Pulitzer Prize, he has worked as an investigative reporter for 30 years, writing articles on politics, medicine, and
health for CBS Healthwatch, LA Weekly, Spin Magazine, Stern, and other newspapers and magazines in the US and Europe. Jon has delivered lectures and seminars on global politics, health, logic, and creative power to audiences around the world.
www.nomorefakenews.comqjrconsulting@gmail.comAbout the author:The author of an explosive new collection, THE MATRIX REVEALED, Jon
was a candidate for a US Congressional seat in the 29th District of
California. Nominated for a Pulitzer Prize, he has worked as an
investigative reporter for 30 years, writing articles on politics,
medicine, and health for CBS Healthwatch, LA Weekly, Spin Magazine,
Stern, and other newspapers and magazines in the US and Europe. Jon
has delivered lectures and seminars on global politics, health, logic,
and creative power to audiences around the world.
www.nomorefakenews.com
Have comments on this article? Post them here:
people have commented on this article.
Email this article to a friend
Now Available from 
